menu search

Autolus therapeutics reports third quarter 2023 financial results and business updates

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymp...

November 2, 2023, 11:11 am

Corvus pharmaceuticals to present new interim soquelitinib data from its phase 1/1b t cell lymphoma trial at the 65th american society of hematology (ash) annual meeting & exposition

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today ...

November 2, 2023, 9:15 am

Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...

November 2, 2023, 2:00 am

Cargo therapeutics begins $100 million ipo rollout

Cargo Therapeutics, Inc. has filed for a $100 million IPO to develop improved CAR T-cell therapy for large B-cell lymphoma. The company's lead candida...

October 23, 2023, 5:47 pm

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/...

October 22, 2023, 8:25 am

Syndax: biotech to watch with regulatory filings before end of 2023

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relap...

October 13, 2023, 2:52 pm

Verastem: signs of life for a beaten-down equity

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is b...

October 4, 2023, 9:00 pm

Regeneron's (regn) application for blood cancer drug accepted

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory f...

August 18, 2023, 2:05 pm

Pfizer gets fda accelerated approval for multiple myeloma treatment

A Pfizer Inc. PFE, +0.52% treatment for relapsed or refractory multiple myeloma has received accelerate...

August 14, 2023, 2:40 pm

Caribou biosciences: positive cb-010 data leads to first half 2024 catalyst

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with ...

July 17, 2023, 5:11 am

Genmab: epkinly's approval not big enough needle-mover (neutral)

Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed<...

June 29, 2023, 10:05 am

Arcellx (aclx) down on hold for lead program cart-ddbcma

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refract...

June 21, 2023, 11:49 am

Arcellx price target slashed, stock takes a hit as fda puts hold on clinical trial following patient death

Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its invest...

June 20, 2023, 4:36 pm

Bristol myers (bmy) announces car t cell therapy breyanzi data

Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in ...

June 19, 2023, 12:29 pm

Roche (rhhby) gets fda approval for blood cancer drug columvi

Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with ...

June 16, 2023, 1:51 pm

Marker therapeutics announces first lymphoma patient treated with mt-601 in phase 1 clinical trial

Marker Therapeutics initiated APOLLO trial for the treatment of lymphoma patients who have relapsed aft...

June 12, 2023, 11:00 am

Kura oncology presents late-breaking clinical data for menin inhibitor ziftomenib at 2023 european hematology association (eha) congress

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (...

June 11, 2023, 7:45 am

Legend (legn) up 4% on snda submission for carvykti expanded use

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with rela...

June 7, 2023, 9:48 am

Why shares of day one pharmaceuticals are up monday

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive p...

June 5, 2023, 12:30 pm

Day one biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat...

June 5, 2023, 8:09 am


Search within

Pages Search Results: